Meng Chen

US Patent:

6613432, Sep 2, 2003

Filed:

Dec 21, 2000

Appl. No.:

09/746234

Inventors:

Paul O. Zamora - Gaithersburg MD
Shigemasa Osaki - Sandy UT
Meng Chen - Salt Lake City UT

Assignee:

BioSurface Engineering Technologies, Inc. - College Park MD

International Classification:

B32B 1504

US Classification:

428409, 427 224, 427539, 428457, 428469, 428544, 428685

Abstract:

Coatings, devices and methods are provided, wherein the contacting surface of a medical device with at least one contacting surface for contacting a bodily fluid or tissue is modified by plasma treatment in a plasma comprising nitrogen-containing molecules and oxygen-containing molecules. The nitrogen-containing molecules include NH , (NH ) , N O, NO, NO and N O , and the oxygen-containing molecules include O and O. The plasma-modified contacting surface exhibits decreased adhesion of at least some mammalian cells, such as platelets and leukocytes, decreased restenosis when used with stents, and increased apoptosis. Additional layers may be applied, including plasma polymerized hydrocyclosiloxane monomers, amine-providing groups such as N-trimethylsilyl-allylamine, polyoxyalkylene tethers, and bioactive compounds.

US Patent:

7410992, Aug 12, 2008

Filed:

Aug 31, 2004

Appl. No.:

10/569921

Inventors:

Meng Hsin Chen - Westfield NJ, US
James B. Doherty - Montvale NJ, US
Luping Liu - Plainsboro NJ, US
Swaminathan Natarajan - Scotch Plains NJ, US
Robert M. Tynebor - Woodbridge NJ, US

Assignee:

Merck & Co. Inc. - Rahway NJ

International Classification:

A61K 31/416
C07D 231/54

US Classification:

514406, 5483581, 5483601, 5483611, 5483615, 514403

Abstract:

This invention relates to potent potassium channel blocker compounds of Formula (I) or a formulation thereof for the treatment of glaucoma and other conditions which leads to elevated intraoccular pressure in the eye of a patient. This invention also relates to the use of such compounds to provide a neuroprotective effect to the eye of mammalian species, particularly humans, or a pharmaceutically acceptable salt, in vivo hydrolysable ester, enantiomer, diastereomer or mixture thereof: formula (II) represents Caryl or Cheterocyclyl, said aryl or heterocyclyl optionally substituted with 1-3 groups selected from R; Z represents (CH)PO(OR)(OR*).

US Patent:

7494983, Feb 24, 2009

Filed:

Aug 31, 2004

Appl. No.:

10/570231

Inventors:

Meng Hsin Chen - Westfield NJ, US
James B. Doherty - Montvale NJ, US
Luping Liu - Plainsboro NJ, US
Swaminathan Natarajan - Scotch Plains NJ, US
Robert M. Tynebor - Woodbridge NJ, US

Assignee:

Merck & Co. Inc. - Rahway NJ

International Classification:

A61K 31/675
A61K 31/4439
C07F 9/06

US Classification:

514 80, 514 89, 514338, 514406, 546 22, 546 24, 548113

Abstract:

This invention relates to potent potassium channel blocker compounds of structural Formula I or a formulation thereof for the treatment of glaucoma and other conditions which leads to elevated intraoccular pressure in the eye of a patient. This invention also relates to the use of such compounds to provide a neuroprotective effect to the eye of mammalian species, particularly humans.

US Patent:

7720131, May 18, 2010

Filed:

Jun 27, 2007

Appl. No.:

11/769537

Inventors:

Vikash Srivastava - Boyds MD, US
Meng Chen - Frederick MD, US

Assignee:

PC-Tel, Inc. - Bloomingdale IL

International Classification:

H04L 27/30

US Classification:

375144, 375148, 375349, 375365, 370503, 455 6711, 4552261

Abstract:

A method and apparatus are provided for decoding a wireless signal from a set of samples with an embedded training sequence. The method includes the steps of determining a first frequency offset from the samples where the first frequency offset is assumed to be less than a Nyquist frequency of the training sequence and calculating a first carrier to interference ratio based upon the first frequency offset. The method further includes the steps of determining a second frequency offset from the samples by subtracting an absolute value of the first frequency offset from an integer multiple of the Nyquist frequency and giving the second frequency offset a sign opposite that of the first frequency offset, calculating a second carrier to interference ratio based upon the second frequency offset and selecting one of the first and second frequency offsets based upon a relative values of the calculated carrier to interference ratios.

US Patent:

20050256117, Nov 17, 2005

Filed:

Jun 11, 2003

Appl. No.:

10/511636

Inventors:

Meng Hsin Chen - Westfield NJ, US
Luping Liu - Palainsboro NJ, US
Peter Meinke - Plainfield NJ, US
Ravi Natarajan - Scotch Plains NJ, US
William Parsons - Belle Mead NJ, US
Min Shu - Green Brook NJ, US
John Stelmach - Westfield NJ, US
Harold Wood - Westfield NJ, US
Fengqi Zhang - Edison NJ, US
David Wisnoski - Lansdale PA, US
James Doherty - Montvale NJ, US

International Classification:

A61K031/5377
A61K031/4439
A61K031/427
C07D417/02
C07D413/02
C07D043/02

US Classification:

514233500, 514370000, 548181000, 514337000, 546270700, 544143000

Abstract:

This invention relates to the use of potent potassium channel blockers or a formulation thereof in the treatment of glaucoma and other conditions which leads to elevated intraoccular pressure in the eye of a patient. This invention also relates to the use of such compounds to provide a neuroprotective effect to the eye of mammalian species, particularly humans.

US Patent:

20060148805, Jul 6, 2006

Filed:

Jun 25, 2004

Appl. No.:

10/561571

Inventors:

Meng Hsin Chen - Westfield NJ, US
James Doherty - Montvale NJ, US
Luping Liu - Plainsboro NJ, US
Swaminathan Natarajan - Scotch Plains NJ, US
Min Shu - Greenbrook NJ, US

International Classification:

A61K 31/522
A61K 31/503
A61K 31/498
A61K 31/4184
C07D 473/10
C07D 471/02
C07D 487/02

US Classification:

514248000, 514249000, 514263380, 514303000, 514394000, 544236000, 544276000, 544330000, 546117000, 548305400

Abstract:

This invention relates to the use of potent potassium channel blockers or a formulation thereof in the treatment of glaucoma and other conditions which leads to elevated intraoccular pressure in the eye of a patient. This invention also relates to the use of such compounds to provide a neuroprotective effect to the eye of mammalian species, particularly humans.

US Patent:

62290541, May 8, 2001

Filed:

Dec 9, 1999

Appl. No.:

9/458229

Inventors:

Zhisheng Dai - Edison NJ
Meng J. Chen - Edison NJ

Assignee:

Cardolite Corporation - Newark NJ

International Classification:

C07C 4100

US Classification:

568630

Abstract:

The present invention comprises a process for the hydroxyalkylation of cardanol with cyclic organic carbonates in the presence of organic or inorganic catalysts and a novel composition of matter produced by that process. The unique molecular structure of cardanol allows the use of a variety of organic or inorganic basic catalysts, including triethylamine, imidazol, sodium hydroxide and sodium carbonate, in the hydroxyalkylation reaction without forming quantities of undesirable side-products. According to this invention, the final product, monohydroxyalkylcardanyl ether, can be obtained with high yield and high purity. The product has a light color and its color stability is enhanced by replacing the phenol's hydroxyl group with a more stable hydroxyalkoxyl group.

US Patent:

59655658, Oct 12, 1999

Filed:

Dec 11, 1997

Appl. No.:

8/988816

Inventors:

Meng H. Chen - Westfield NJ
Zhijian Lu - Scotch Plains NJ
Ravi Nargund - East Brunswick NJ
Arthur A. Patchett - Westfield NJ
James R. Tata - Westfield NJ
Lihu Yang - Edison NJ
Mu Tsu Wu - Clark NJ

Assignee:

Merck & Co., Inc. - Rahway NJ

International Classification:

C07D20904
C07D21100
A61K 31445

US Classification:

514278

Abstract:

The present invention is directed to certain piperidines, pyrrolidines, and hexahydro-1H-azepines of the general structural formula: ##STR1## wherein B is selected from: ##STR2## and R. sup. 1, R. sup. 1a, R. sup. 2a, R. sup. 3a, R. sup. 3b, R. sup. 4, R. sup. 4a, R. sup. 4b, R. sup. 4c, R. sup. 5, D, X, Y, n, x and y are as defined herein. These compounds promote the release of growth hormone in humans and animals. This property can be utilized to promote the growth of food animals to render the production of edible meat products more efficient, and in humans, to treat physiological or medical conditions characterized by a deficiency in growth hormone secretion, such as short stature in growth hormone deficient children, and to treat medical conditions which are improved by the anabolic effects of growth hormone. Growth hormone releasing compositions containing such compounds as the active ingredient thereof are also disclosed.